^
Association details:
| Biomarker: | IDH2 R172G |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Idhifa (enasidenib) (IDH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficient anti-tumor activity of Enasidenib in mutant IDH2 patient-derived models of chondrosarcoma
Published date:
05/28/2021
Excerpt:
...while IDH2R172G was present in CDS17 and T-CDS17 lines...enasidenib was able reduce 2-HG levels and to eliminate mIDH2 cells at low micromolar concentrations. Moreover, enasidenib was able to target cancer stem cell-enriched 3D cultures. Finally, oral administration of enasidenid in T-CDS17-xenografted mice resulted in a significant reduction of tumor growth while increasing chondrogenic differentiation...Enasidenib may constitute an efficient treatment for mIDH2 CS.
